CDC

ACIP endorses use of 21-valent pneuomococcal conjugate vaccine

July 2, 2024

Pneumococcal Vaccines

PCV21 covers 81% of the pneumococcal serotypes commonly found in adults and gives clinicians another option for protecting adult patients from pneumococcal infections.

• ACIP voted 11-0 to recommend PCV21 as an option for adults ≥19 years of age who currently have a recommendation to receive a dose of PCV.

Respiratory Syncytial Virus Vaccines – Adults

• ACIP voted 11-0 to recommend adults ≥75 years of age receive a single dose of RSV vaccine.
• ACIP voted 11-0 to recommend adults ages 60 to 74 who are at increased risk of severe RSV disease receive a single dose of RSV vaccine. These include people with certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes.

Vaxelis

• ACIP voted 11-0 to recommend that Vaxelis be included with PRP-OMP (PedvaxHIB) in the preferential recommendation for American Indian and Alaska Native (AI/AN) infants based on Hib component.

COVID-19 Vaccine

• ACIP voted 11-0 to recommend the updated 2024-2025 COVID-19 vaccine as authorized or approved by FDA in persons ≥6 months of age.

Influenza Vaccines

• ACIP voted 11-0 to recommend routine vaccination for everyone ≥6 months of age.
• ACIP voted 11-0 to recommend that high-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines are acceptable options for influenza vaccination of solid organ transplant recipients who are 18 to 64 years old and who are taking immunosuppressive medications, without a preference over other age appropriate inactivated or recombinant influenza vaccines.

Source:

CDC. (2024, June 28). Readout of Advisory Committee on Immunization Practices Meeting Held June 26 – 28, 2024. https://www.cdc.gov/media/releases/2024/s-0627-immunization-practices-meeting.html